U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07189910) titled 'Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP' on Aug. 12.
Brief Summary: To address the clinical need for improving early response rates, maintaining sustained responses, reducing relapse rates, and minimizing adverse events in the treatment of immune thrombocytopenia (ITP), the investigators developed a comprehensive in-hospital and post-discharge management strategy. In this study, hospitalized participants will receive a 14-day regimen of high-dose dexamethasone (HD-DXM) plus recombinant human thrombopoietin (rhTPO), followed by a 10-week course of oral eltrombopag olamine dry suspension after ...